Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan:65:59-64.
doi: 10.1016/j.annepidem.2021.10.004. Epub 2021 Oct 23.

Hepatitis C mortality trends in San Francisco: can we reach elimination targets?

Ali Mirzazadeh  1 , Shelley N Facente  2 , Katie Burk  3 , James G Kahn  4 , Meghan D Morris  5 ; End Hep C SF
Affiliations

Hepatitis C mortality trends in San Francisco: can we reach elimination targets?

Ali Mirzazadeh et al. Ann Epidemiol. 2022 Jan.

Abstract

Purpose: Hepatitis C virus (HCV) is the most common blood-borne infection in the United States, and a leading cause of liver disease, transplant, and mortality. CDC HCV elimination goals include reducing HCV-related mortality by 65% (from 2015) by 2030.

Methods: We used vital registry data (CDC WONDER) to estimate overall and demographic-specific HCV-related mortality from 1999 to 2019 in San Francisco and then used an exponential model to project progress toward HCV elimination. Local trends were compared to state and national trends.

Results: Between 1999 and 2019, there were 1819 HCV-related deaths in San Francisco, representing an overall age-adjusted mortality rate of 9.4 (95% CI 9.0, 9.9) per 100,000 population. The age-adjusted HCV-related mortality rates were significantly higher among males (13.7), persons aged 55 years and older (28.0), Black and/or African Americans (32.2) compared to other racial groups, and Hispanic/Latinos (11.6) compared to non-Hispanic and/or Latinos. Overall and in most subgroups, mortality rates were lowest between 2015 and 2019. Since 2015, San Francisco observed a significantly larger reduction in agbe-adjusted HCV-related mortality than California or the U.S. Projected age-adjusted HCV-related mortality rates for San Francisco for 2020 and 2030 were 4.7 (95% CI 3.5, 6.2) and 1.1 (95% CI 0.7, 1.8), respectively.

Conclusions: Based on trends between 2015 and 2019, San Francisco, California, and the U.S. are projected to achieve 65% reduction in HCV-mortality at or before 2030. Based on current trends, San Francisco is projected to achieve this goal earlier.

Keywords: Hcv elimination targets; Hepatitis c; Mortality.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1.
Fig. 1.
San Francisco County Hepatitis C Mortality Rates for Baby Boomers Birth Cohort (People born 1945–1965) by year.
Fig. 2.
Fig. 2.
Hepatitis C mortality in San Francisco, California, and the United States, 1999 to 2019.
Fig. 3.
Fig. 3.
Projection of age-adjusted HCV-related mortality in San Francisco, California and the United States till 2030 against elimination targets. Footnote: Observed data (point estimates, lower and upper limits: red color) in 2015–2019 were projected till 2030 using exponential models. The elimination target for 2020 was a 10% reduction in HCV-related mortality observed for 2015 and the elimination target for 2030 was a 65% reduction in HCV-related mortality observed for 2015.
See this image and copyright information in PMC

References

    1. Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, et al. Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016. JAMA Netw Open 2018;1(8):e186371. - PMC - PubMed
    1. Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013–2016. Hepatology 2019;69(3):1020–31. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance — United States, 2018. Available at: https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm. Published July 2020. Accessed 10/15/2020. 2018.
    1. Abara WE, Trujillo L, Broz D, Finlayson T, Teshale E, Paz-Bailey G, et al. Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015. J Infect Dis 2019;220(3):377–85. - PMC - PubMed
    1. Ly KN, Miniño AM, Liu SJ, Roberts H, Hughes EM, Ward JW, et al. Deaths Associated With Hepatitis C Virus Infection Among Residents in 50 States and the District of Columbia, 2016–2017. Clin Infect Dis 2020;71(5):1149–60. - PMC - PubMed

Publication types